ReviewCalcified tissue international2019
Paget's Disease of Bone.
Review in Calcified tissue international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- Pooled it
- Role of Denosumab in Chronic Kidney Disease with Paget's Disease of Bone: A Case Report and Review of Literature.Journal of orthopaedic case reports · 2026Article
- Severe hypocalcemia in a patient with extensive cranial Paget disease: a diagnostic challenge.JCEM case reports · 2026Article
- Review
- Paget's disease of bone in a North African population: clinical, imaging, and therapeutic insights from a Moroccan case series.Clinical rheumatology · 2026Review
- Case Report: Gastrointestinal cancer initially presenting as postmenopausal osteoporosis.Frontiers in oncology · 2026Article
- A Missense Mutation in Close Proximity of ALS-linked PFN1 Mutations Causes Only Early-onset Paget Disease of Bone.The Journal of clinical endocrinology and metabolism · 2025Article
- Latest developments in Paget's disease of bone.European journal of endocrinology · 2025Review
- A practical use of bone turnover markers in management of patients with skeletal fragility.Endocrine · 2025Review
- Review
- Standard and advanced echocardiographic study of patients with Paget's disease of bone: Evidence of a pagetic heart disease?Journal of internal medicine · 2025Article
- Treatment of Extraosseous Giant Cell Tumor of Bone and Calcitriol-Mediated Hypercalcemia With Denosumab in Paget Disease.JCEM case reports · 2025Article
- Epigenetic Regulation ofInternational journal of molecular sciences · 2025Article
- Development of Paget's disease of bone in adults inheritingJBMR plus · 2025Article
- Paget's bone disease in a nonendemic region: Exploring novel therapeutic strategies.Clinical case reports · 2024Article
- From bimodal to unimodal: The transformed incidence of osteosarcoma in the United States.Journal of bone oncology · 2024Article
- Review
- Diagnosis and treatment of Paget's disease of bone: position paper from the Italian Society of Osteoporosis, Mineral Metabolism and Skeletal Diseases (SIOMMMS).Journal of endocrinological investigation · 2024Review
- Paget Disease of Bone Harboring Bone Metastatic Neuroendocrine Cancer: A Case Report.Calcified tissue international · 2024Article
- Subchondral osteoclasts and osteoarthritis: new insights and potential therapeutic avenues.Acta biochimica et biophysica Sinica · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paget's disease of bone (PDB) is a chronic and focal bone disorder, characterized by increased osteoclast-mediated bone resorption and a subsequent compensatory increase in bone formation, resulting in a disorganized mosaic of woven and lamellar bone at one or more affected skeletal sites. As a result, bone pain, noticeable deformities, arthritis at adjacent joints, and fractures can occur. In a small proportion of cases neoplastic degeneration in osteosarcoma, or, less frequently, giant cell tumor has been also described at PDB sites. While recent epidemiological evidences clearly indicate a decrease in the prevalence and the severity of PDB, over the past 2 decades there have been consistent advances on the genetic mechanisms of disease. It is now clear that PDB is a genetically heterogeneous disorder, with mutations in at least two different genes (SQSTM1, ZNF687) and more common predisposing variants. As a counterpart to the genetic hypothesis, the focal nature of lesions, the decline in prevalence rates, and the incomplete penetrance of the disease among family members suggest that one or more environmental triggers may play a role in the pathophysiology of PDB. The exact nature of these triggers and how they might interact with the genetic factors are less understood, but recent experimental data from mice models suggest the implication of paramixoviral infections. The clinical management of PDB has also evolved considerably, with the development of potent aminobisphosphonates such as zoledronic acid which, given as a single intravenous infusion, now allows a long-term disease remission in the majority of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.